Jubilant Pharma Limited Officer-Qa Position Apply Now
Jubilant
Pharma Limited is a global integrated pharmaceutical company offering a wide
range of products and services to its customers across geographies. We organise
our business into two segments, namely, Specialty Pharmaceuticals, comprising
Radiopharmaceuticals (including Radio pharmacies), Contract Manufacturing of
Sterile Injectable, Non-sterile & Allergy Therapy Products, and Generics
& APIs, comprising Solid Dosage Formulations & Active Pharmaceutical
Ingredients.
Jubilant
Generics (JGL) is a wholly - owned subsidiary of Jubilant Pharma. JGL in India
has Research & Development units at Noida and Mysore. It has two
manufacturing facilities one at Mysore, Karnataka and another at Roorkee,
Uttarakhand, engaged in APIs and Dosage manufacturing, respectively.
The
manufacturing location at Mysore is spread over 69 acres and it’s a USFDA
approved site engaged in manufacturing of APIs, and caters to the sales
worldwide. API portfolio focusses on Lifestyle driven Therapeutic Areas (CVS,
CNS) and targets complex and newly approved molecules. The company is the
market leader in four APIs and is amongst the top three players for another
three APIs in its portfolio helping it maintain a high contribution margin. The
manufacturing location at Roorkee, Uttarakhand is state of the art facility and
is audited and approved by USFDA, Japan PMDA, UK MHRA, TGA, WHO and Brazil
ANVISA. This business focusses on B2B model for EU, Canada and emerging
markets.
Both
manufacturing units are backward- integrated and are supported by around 500
research and development professionals based at Noida and Mysore. R&D works
on Development of new products in API, Solid Dosage Formulations of Oral Solid,
Sterile Injectable, Semi-Solids Ointments, Creams and Liquids. All BA/BE
studies are done In house at our 80 Bed facility which is inspected and having
approvals /certifications from The Drugs Controller General (India) and has
global regulatory accreditations including USFDA, EMEA, ANVISA (Brazil),
INFRAMED (Portugal Authority), NPRA(Malaysia), AGES MEA (Austria) for GCP and
NABL, CAP accreditations for Path lab services.
JGL’s
full-fledged Regulatory Affairs & IPR professionals ensures unique
portfolio of patents and product filings in regulatory and non-regulatory
market.
Revenue of
Jubilant Pharma is constantly increasing and during the Financial Year 2018 -19
it was INR 53,240 Million as compared to INR 39,950 Million during the
Financial Year 2017-18.
Kindly refer
www.jubilantpharma.com for more information about organization.
TO APPLY CLICK HERE
FOR MORE JOB UPDATES
No comments:
Post a Comment